154 related articles for article (PubMed ID: 8354335)
21. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
22. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
23. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
Mol MJ; Stuyt PM; Demacker PN; Stalenhoef AF
Neth J Med; 1990 Apr; 36(3-4):182-90. PubMed ID: 2355995
[TBL] [Abstract][Full Text] [Related]
24. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
Hagemenas FC; Pappu AS; Illingworth DR
Eur J Clin Invest; 1990 Apr; 20(2):150-7. PubMed ID: 2112479
[TBL] [Abstract][Full Text] [Related]
25. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
[TBL] [Abstract][Full Text] [Related]
26. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Bargossi AM; Grossi G; Fiorella PL; Gaddi A; Di Giulio R; Battino M
Mol Aspects Med; 1994; 15 Suppl():s187-93. PubMed ID: 7752830
[TBL] [Abstract][Full Text] [Related]
27. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
Ordovas JM; Lopez-Miranda J; Perez-Jimenez F; Rodriguez C; Park JS; Cole T; Schaefer EJ
Atherosclerosis; 1995 Mar; 113(2):157-66. PubMed ID: 7605354
[TBL] [Abstract][Full Text] [Related]
28. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
29. [Effects of simvastatin on atherogenic blood lipid pattern].
Alessandri C; Peverini F; Basili S; Barsi R; Paradiso M; Marotta P; Censi C; Cordova C; Balsano F
Recenti Prog Med; 1991 Apr; 82(4):225-9. PubMed ID: 1857842
[TBL] [Abstract][Full Text] [Related]
30. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
31. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
32. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
33. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
[TBL] [Abstract][Full Text] [Related]
34. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
Pedreño J; Sánchez JL; Zambón D; Ros E
Coron Artery Dis; 1994 Dec; 5(12):971-7. PubMed ID: 7728297
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
[TBL] [Abstract][Full Text] [Related]
36. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
Thiery J; Armstrong VW; Schleef J; Creutzfeldt C; Creutzfeldt W; Seidel D
Klin Wochenschr; 1988 May; 66(10):462-3. PubMed ID: 2969433
[No Abstract] [Full Text] [Related]
37. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
39. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
Warwick GL; Packard CJ; Murray L; Grierson D; Stewart JP; Shepherd J; Boulton-Jones JM
Clin Sci (Lond); 1992 Jun; 82(6):701-8. PubMed ID: 1320552
[TBL] [Abstract][Full Text] [Related]
40. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
